Insmed Ownership

INSM Stock  USD 26.18  0.03  0.11%   
Insmed secures a total of 148.56 Million outstanding shares. The majority of Insmed Inc outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Insmed to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Insmed Inc. Please pay attention to any change in the institutional holdings of Insmed Inc as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
 
Shares in Circulation  
First Issued
1999-03-31
Previous Quarter
142.9 M
Current Value
144.8 M
Avarage Shares Outstanding
42.1 M
Quarterly Volatility
42.4 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Insmed in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Insmed, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
As of the 18th of April 2024, Dividend Paid And Capex Coverage Ratio is likely to grow to 47.61. As of the 18th of April 2024, Common Stock Shares Outstanding is likely to grow to about 147.5 M, though Net Loss is likely to grow to (411.7 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Insmed Stock Ownership Analysis

About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.34. Insmed Inc had not issued any dividends in recent years. The entity had 1:10 split on the 3rd of March 2011. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 613 people. To learn more about Insmed Inc call William Lewis at 908 977 9900 or check out https://www.insmed.com.
Besides selling stocks to institutional investors, Insmed also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Insmed's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Insmed's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Insmed Quarterly Liabilities And Stockholders Equity

1.33 Billion

Insmed Insider Trades History

Only 1.08% of Insmed Inc are currently held by insiders. Unlike Insmed's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Insmed's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Insmed's insider trades
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Insmed Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Insmed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insmed Inc backward and forwards among themselves. Insmed's institutional investor refers to the entity that pools money to purchase Insmed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Geode Capital Management, Llc2023-12-31
3.1 M
Suvretta Capital Management, Llc2023-12-31
2.7 M
Bank Of New York Mellon Corp2023-12-31
2.4 M
Loomis, Sayles & Company Lp2023-12-31
2.3 M
Bellevue Group Ag2023-12-31
2.3 M
Ameriprise Financial Inc2023-12-31
2.3 M
Alliancebernstein L.p.2023-12-31
2.1 M
Pictet Asset Manangement Sa2023-12-31
M
Rtw Investments, Llc2023-12-31
1.9 M
Vanguard Group Inc2023-12-31
14.1 M
Blackrock Inc2023-12-31
11.5 M
Note, although Insmed's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Insmed Inc Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insmed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Insmed Corporate Filings

1st of April 2024
Other Reports
ViewVerify
8K
11th of March 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
29th of February 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10K
22nd of February 2024
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
ViewVerify

Insmed Investors Sentiment

The influence of Insmed's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Insmed. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Insmed's public news can be used to forecast risks associated with an investment in Insmed. The trend in average sentiment can be used to explain how an investor holding Insmed can time the market purely based on public headlines and social activities around Insmed Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Insmed's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Insmed's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Insmed's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Insmed.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Insmed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Insmed's short interest history, or implied volatility extrapolated from Insmed options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Insmed Inc is a strong investment it is important to analyze Insmed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insmed's future performance. For an informed investment choice regarding Insmed Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Insmed Stock analysis

When running Insmed's price analysis, check to measure Insmed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insmed is operating at the current time. Most of Insmed's value examination focuses on studying past and present price action to predict the probability of Insmed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insmed's price. Additionally, you may evaluate how the addition of Insmed to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Insmed's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.34)
Revenue Per Share
2.173
Quarterly Revenue Growth
0.411
Return On Assets
(0.28)
Return On Equity
(14.53)
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.